ForteBio Inc., of Menlo Park, Calif., named Joseph Keegan president and CEO.

F-star, of Vienna, Austria, appointed Geert Mudde chief scientific officer.

Gemin X Pharmaceuticals Inc., of Malvern, Pa., appointed Eric Roberts to its board.

Genaera Corp., of Plymouth Meeting, Pa., elected Mitchell Kaye to its board and appointed Henry Wolfe executive vice president and chief scientific officer and Michael Gast executive vice president and chief medical officer.

Genencor, of Rochester, N.Y., a division of Danisco A/S, appointed Glenn Nedwin executive vice president of technical enzymes.

Gene Express Inc., of Toledo, Ohio, appointed David Lester senior vice president of strategy and corporate development.

Gen-Probe, of San Diego, elected John Martin to its board.

Helicos BioSciences Corp., of Cambridge, Mass., promoted Stephen Lombardi to president and CEO.

Idera Pharmaceuticals Inc., of Cambridge, Mass., elected Hans Mueller to its board.

Ikaria Holdings Inc., of Clinton, N.J., appointed Ralf Rosskamp executive vice president of research and development.

ImaRx Therapeutics Inc., of Tucson, Ariz., named Richard Love as chairman. The firm also named Garen Manyelian chief medical officer and promoted Jennifer Marshall to vice president of corporate development.

ImmunoGen Inc., of Cambridge, Mass., named Craig Barrows vice president, general counsel and secretary.

ImmunoVaccine Technologies Inc., of Halifax, Nova Scotia, appointed Neil Berinstein to its scientific advisory board.

InSite Vision Inc., of Alameda, Calif., appointed Louis Drapeau vice president and chief financial officer.

IntegraGen SA, of Paris, appointed Bernard Courtieu CEO.

Keryx Biopharmaceuticals Inc., of New York, appointed Michael Tarnok to its board.